Literature DB >> 28653207

[Familial exsudative vitreoretinopathy (FEVR) in childhood].

A E Laubichler1, P Laubichler2, D Zapp3, M Klopfer3, M Ulbig3.   

Abstract

A case of secondary neovascularization of the optic disc in familial exsudative vitreoretinopathy (FEVR) is reported. A 12-year-old girl presented with decreased visual acuity of the right eye to 0.05. Funduscopy showed a prominent fibrovascular neovascularization of the optic disc covering the macula. Fluorescein angiography demonstrated circular peripheral ischemia as well as vascular anomalies in both eyes. Peripheral laser coagulation of the ischemic retina of the right eye was conducted with the patient under general anesthesia. The central neovascularization regressed and visual acuity increased up to 0.4. Molecular genetic examination detected the LRP5 gene for FEVR.

Entities:  

Keywords:  Fluorescein angiography; Hereditary eye diseases; Laser coagulation; Molecular genetics; Retinal neovascularization

Mesh:

Year:  2018        PMID: 28653207     DOI: 10.1007/s00347-017-0527-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

1.  Progression of familial exudative vitreoretinopathy after laser treatment.

Authors:  Ron Margolis; Stephen S Couvillion; Elias C Mavrofrides; Ditte Hess; Timothy G Murray
Journal:  Arch Ophthalmol       Date:  2004-11

2.  Familial Exudative Vitreoretinopathy: Spectral-Domain Optical Coherence Tomography of the Vitreoretinal Interface, Retina, and Choroid.

Authors:  Yoshihiro Yonekawa; Benjamin J Thomas; Kimberly A Drenser; Michael T Trese; Antonio Capone
Journal:  Ophthalmology       Date:  2015-08-20       Impact factor: 12.079

3.  Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: a single surgeon's experience.

Authors:  Mumin Hocaoglu; Murat Karacorlu; Isil Sayman Muslubas; Mehmet Giray Ersoz; Serra Arf
Journal:  Br J Ophthalmol       Date:  2016-10-28       Impact factor: 4.638

4.  Bevacizumab for the treatment of pediatric retinal and choroidal diseases.

Authors:  Robert A Sisk; Audina M Berrocal; Thomas A Albini; Timothy G Murray
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2010-08-30

Review 5.  Familial exudative vitreoretinopathy and related retinopathies.

Authors:  D F Gilmour
Journal:  Eye (Lond)       Date:  2014-10-17       Impact factor: 3.775

6.  Retinopathy of Prematurity Versus Familial Exudative Vitreoretinopathy: Report on Clinical and Angiographic Findings.

Authors:  Vishak J John; Jedediah I McClintic; Ditte J Hess; Audina M Berrocal
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-01       Impact factor: 1.300

7.  Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.

Authors:  Mizuki Tagami; Sentaro Kusuhara; Shigeru Honda; Yasutomo Tsukahara; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-16       Impact factor: 3.117

8.  Familial exudative vitreoretinopathy (FEVR). Clinical profile and management.

Authors:  Dhananjay Shukla; Jatinder Singh; G Sudheer; Manoj Soman; Rajesh K John; Kim Ramasamy; Namperumalsamy Perumalsamy
Journal:  Indian J Ophthalmol       Date:  2003-12       Impact factor: 1.848

Review 9.  [Retinal exudative disease in childhood: Coats' disease and familial exudative vitreoretinopathy (FEVR)].

Authors:  A M Joussen; R S Gordes; F A Heußen; B Müller
Journal:  Klin Monbl Augenheilkd       Date:  2013-08-28       Impact factor: 0.700

10.  High prevalence of peripheral retinal vascular anomalies in family members of patients with familial exudative vitreoretinopathy.

Authors:  Amir H Kashani; Daniel Learned; Eric Nudleman; Kimberly A Drenser; Antonio Capone; Michael T Trese
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

  10 in total
  1 in total

1.  Long-term clinical prognosis of 335 infant single-gene positive FEVR cases.

Authors:  Chunli Chen; Yizhe Cheng; Zhihan Zhang; Xiang Zhang; Jiakai Li; Peiquan Zhao; Xiaoyan Peng
Journal:  BMC Ophthalmol       Date:  2022-08-02       Impact factor: 2.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.